P
Phuc Felix Nguyen-Tan
Researcher at Université de Montréal
Publications - 53
Citations - 3297
Phuc Felix Nguyen-Tan is an academic researcher from Université de Montréal. The author has contributed to research in topics: Head and neck squamous-cell carcinoma & Cancer. The author has an hindex of 22, co-authored 53 publications receiving 2747 citations. Previous affiliations of Phuc Felix Nguyen-Tan include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
K. Kian Ang,Qiang Zhang,David I. Rosenthal,Phuc Felix Nguyen-Tan,Eric J. Sherman,Randal S. Weber,James M. Galvin,James A. Bonner,Jonathan Harris,Adel K. El-Naggar,Maura L. Gillison,Richard C.K. Jordan,Andre Konski,Wade L. Thorstad,Andy Trotti,Jonathan J. Beitler,Adam S. Garden,William J. Spanos,Sue S. Yom,Rita Axelrod +19 more
TL;DR: Adding cetuximab to radiation-cisplatin did not improve outcome and hence should not be prescribed routinely, and the PFS and OS were higher in patients with p16-positive OPC, but outcomes did not differ by EGFR expression.
Journal ArticleDOI
Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma
Carole Fakhry,Qiang Zhang,Phuc Felix Nguyen-Tan,David I. Rosenthal,Adel K. El-Naggar,Adam S. Garden,Denis Soulières,Andy Trotti,Vilija N. Avizonis,John A. Ridge,Jonathan Harris,Quynh-Thu Le,Maura L. Gillison +12 more
TL;DR: Tumor HPV status is a strong and independent predictor of OS after disease progression and should be a stratification factor for clinical trials for patients with recurrent or metastatic OPC.
Journal ArticleDOI
Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer
Martin Vallières,Emily Kay-Rivest,Léo Jean Perrin,Xavier Liem,Christophe Furstoss,Hugo J.W.L. Aerts,Nader Khaouam,Phuc Felix Nguyen-Tan,Chang Shu Wang,K. Sultanem,Jan Seuntjens,Issam El Naqa +11 more
TL;DR: In this article, 1615 radiomic features extracted from pre-treatment FDG-PET and CT images of 300 patients from four different cohorts were analyzed for the risk assessment of locoregional recurrences (LR) and distant metastases (DM) in head-and-neck cancer.
Journal ArticleDOI
Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity
Phuc Felix Nguyen-Tan,Qiang Zhang,K. Kian Ang,Randal S. Weber,David I. Rosenthal,Denis Soulières,Harold Kim,Craig L. Silverman,Adam Raben,Thomas J. Galloway,André Fortin,Elizabeth Gore,William H. Westra,Christine H. Chung,Richard C.K. Jordan,Maura L. Gillison,M. A. List,Quynh-Thu Le +17 more
TL;DR: Long-term high survival rates in p16-positive patients with oropharyngeal cancer support the ongoing efforts to explore deintensification and neither improved outcome nor increased late toxicity in patients with LA-HNC when combined with cisplatin.
Journal ArticleDOI
Institutional Clinical Trial Accrual Volume and Survival of Patients With Head and Neck Cancer
Evan Wuthrick,Qiang Zhang,Mitchell Machtay,David I. Rosenthal,Phuc Felix Nguyen-Tan,André Fortin,Craig L. Silverman,Adam Raben,Harold Kim,Eric M. Horwitz,Nancy Read,Jonathan Harris,Qian Wu,Quynh-Thu Le,Maura L. Gillison +14 more
TL;DR: OS is worse for patients with HNC treated at HLACs versus HHACs to cooperative group trials after accounting for radiotherapy protocol deviations, and Institutional experience substantially influences survival in locally advanced HNC.